PMID: 14633779Nov 25, 2003Paper

Pediatric acute lymphoblastic leukemia

William L CarrollJohn C Reed


The outcome for children with acute lymphoblastic leukemia (ALL) has improved dramatically with current therapy resulting in an event free survival exceeding 75% for most patients. However significant challenges remain including developing better methods to predict which patients can be cured with less toxic treatment and which ones will benefit from augmented therapy. In addition, 25% of patients fail therapy and novel treatments that are focused on undermining specifically the leukemic process are needed urgently. In Section I, Dr. Carroll reviews current approaches to risk classification and proposes a system that incorporates well-established clinical parameters, genetic lesions of the blast as well as early response parameters. He then provides an overview of emerging technologies in genomics and proteomics and how they might lead to more rational, biologically based classification systems. In Section II, Drs. Mary Relling and Stella Davies describe emerging findings that relate to host features that influence outcome, the role of inherited germline variation. They highlight technical breakthroughs in assessing germline differences among patients. Polymorphisms of drug metabolizing genes have been shown to influence toxici...Continue Reading


Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R TrueworthyM Haggard
Nov 7, 1991·The New England Journal of Medicine·J P NegliaG D Hammond
Jan 1, 1985·Pharmacology & Therapeutics·I D Goldman, L H Matherly
Jan 1, 1989·Advances in Enzyme Regulation·J R BertinoY M Chang
Jan 1, 1986·Medical and Pediatric Oncology·D HammondS Siegel
Jan 1, 1986·Medical and Pediatric Oncology·H N Sather
Nov 3, 1983·The New England Journal of Medicine·J JolivetB A Chabner
Aug 26, 1993·Nature·J OgasawaraS Nagata
Jan 1, 1994·Clinical Pharmacology and Therapeutics·H L McLeodW E Evans
Oct 1, 1995·Chemical Research in Toxicology·H A DirvenP J van Bladeren
Feb 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M SmithS E Sallan
Aug 1, 1996·QJM : Monthly Journal of the Association of Physicians·D L HarmonA E Evans
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Y M RustumS Seeber
Jul 1, 1997·Clinical Pharmacology and Therapeutics·D OtternessR Weinshilboum
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F M UckunN A Heerema
Jun 17, 1998·Genes & Development·V Cryns, J Yuan
Aug 27, 1998·The New England Journal of Medicine·C H Pui, W E Evans
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Aug 28, 1998·Science·G Evan, T Littlewood
Aug 28, 1998·Science·N A Thornberry, Y Lazebnik
Aug 28, 1998·Science·D R Green, J C Reed
Sep 2, 1998·Current Opinion in Immunology·R Bellamy, A V Hill
Nov 7, 1998·Nature Genetics·Z G WangP P Pandolfi

❮ Previous
Next ❯


Jun 28, 2011·Human Genetics·Kenneth Offit
May 18, 2005·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Maurice N KhalilGritta E Janka-Schaub
Aug 6, 2004·The New England Journal of Medicine·Naomi J WinickStephen P Hunger
May 10, 2008·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ShivakumarM Wetzler
Sep 28, 2006·BMC Cancer·Katrin HoffmannUrsula R Kees
Jul 16, 2013·Journal of Hematology & Oncology·Maria BraoudakiFotini Tzortzatou-Stathopoulou
Nov 6, 2007·Pharmacogenomics·Anwar HusainDavid W Hein
Aug 27, 2014·Pharmacogenomics·Elixabet Lopez-LopezAfrica Garcia-Orad
Sep 17, 2005·Pediatric Hematology and Oncology·Zakia Al-LamkiJudith F Margolin
Jul 19, 2011·Cytokine & Growth Factor Reviews·Claudia Cocco, Irma Airoldi
Dec 23, 2008·Cancer Genetics and Cytogenetics·Paulo R G ZenGiorgio A Paskulin
Feb 19, 2008·Current Problems in Pediatric and Adolescent Health Care·Patrick A Zweidler-McKay, Joanne M Hilden
May 29, 2008·Pediatric Blood & Cancer·L'aurelle A Johnson, Julie A Ross
Nov 30, 2012·International Journal of Laboratory Hematology·S HutspardolS Hongeng
Apr 25, 2014·European Journal of Haematology·Kai-Ling WangZhi-Gang Li
Jun 19, 2004·Hematology·Geertruy Te KronnieGiuseppe Basso
Sep 23, 2014·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·Marie-Cécile ValéraFréderic Vaysse
May 5, 2007·Journal of Bioinformatics and Computational Biology·Erik AndriesCheryl Willman
Jul 27, 2006·Technology in Cancer Research & Treatment·Xingwei WangBin Zheng
Oct 8, 2004·Pharmacogenomics·Maja Krajinovic, Albert Moghrabi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.


Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.